Eleonora Dondossola

Aug 23, 2024 | digitalcommons.library.tmc.edu | Andrew Hahn |Bilal Siddiqui |Javier Leo |Eleonora Dondossola

AbstractGiven the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-targeted therapies have been the backbone of prostate cancer treatment for over 50 years. New data indicate that AR is expressed in additional cell types within the tumor microenvironment. Moreover, targeting AR for the treatment of prostate cancer has established side effects such as bone complications and an increased risk of developing cardiometabolic disease, indicating broader roles for AR.

Aug 23, 2024 | digitalcommons.library.tmc.edu | Javier Leo |Eleonora Dondossola |Kaitlin J. Basham |Nathaniel Wilson

The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens include some form of AR modulation. In this regard, AR remains the central driver of prostate cancer cell biology. Emerging preclinical and clinical data implicate key roles for AR in additional cancer types, thereby expanding the importance of this drug target beyond prostate cancer.

Feb 19, 2024 | onclive.com | Eleonora Dondossola

Eleonora Dondossola, PhD, assistant professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of studying bone metastasis in renal cell carcinoma (RCC) and other genitourinary cancers. Dondossola and her colleagues in the Bone Metastasis Lab are dedicated to studying the lethal consequences of bone metastasis in patients with prostate and renal cancer.